Search
Close this search box.
Search
[custom_company_search_form]
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%
Lithium
46.07
1.86%
Gold
2,645.80
(0.38%)
Copper
4.52
0.4%
Oil
74.38
0.58%
Bitcoin
62,079.09
0.02%
FTSE 100
8,280.60
(0.02%)
Nikkei 225
38,635.62
0.11%
Dow Jones
42,352.75
0.25%
Iron Ore
108.70
(0.29%)
USD/AUD
0.69
0%
Hang Seng
22,736.87
3.28%

Neurotech International Ltd

NTI

ASX

Neurotech International Limited (NTI) operates as a clinical-stage biopharmaceutical development company with a primary focus on paediatric neurological disorders. Its core mission involves the advancement of research and the development of innovative therapies aimed at enhancing the quality of life for children affected by these conditions. NTI is committed to both the development and commercialisation of novel neurological treatments, leveraging its expertise to provide compassionate care and meaningful advancements in paediatric neurology.

Latest Posts

Line Chart with Gradient
Price
$0.00
-0.009 (-15.52%)
At Close 01/01 (AEST)
Related Companies
4DMEDICAL LIMITED
$4DX
ATOMO DIAGNOSTICS LIMITED
$AT1
OSTEOPORE LIMITED
$OSX
USCOM LIMITED
$UCM
ANSELL LIMITED
$ANN

Latest Posts

neurotech-international-asx-nti-to-pursue-targeted-global-partnering-strategy-and-registration-directed-initiatives-in-australia-nti
Health Care $NTI

Neurotech International (ASX: $NTI) to pursue targeted global partnering strategy and registration-directed initiatives in australia

Company to secure strategic partnerships for NTI164 and pursue multiple registrations in Australia

August 12, 2024
neurotech-international-asx-nti-reports-positive-clinical-trial-results-in-paediatric-neurological-disorders-nti
Health Care $NTI

Neurotech International (ASX: $NTI) reports positive clinical trial results in paediatric neurological disorders

Clinical trial data shows significant improvements in ASD and Rett Syndrome patients

July 25, 2024
neurotech-international-asx-nti-demonstrates-significant-improvements-in-asd-patients-nti
Health Care $NTI

Neurotech International (ASX: $NTI) demonstrates significant improvements in ASD patients

Phase II/III clinical trial shows 56% improvement in ASD symptoms after 12 weeks of NTI164 therapy

July 10, 2024
neurotech-international-asx-nti-reports-clinical-improvement-in-pandas-pans-patients-nti
Health Care $NTI

Neurotech International (ASX: $NTI) reports clinical improvement in PANDAS/PANS patients

NTI164 treatment shows significant improvements in anxiety and depression in children with PANDAS/PANS

June 6, 2024
neurotech-international-asx-nti-reports-clinical-benefits-in-rett-syndrome-trial-nti
Health Care $NTI

Neurotech International (ASX: $NTI) reports clinical benefits in rett syndrome trial

NTI164 shows significant improvement in Rett Syndrome patients after 12-week trial period

May 6, 2024
neurotech-international-asx-nti-extends-clinical-trials-in-paediatric-neurological-disorders-nti
Health Care $NTI

Neurotech International (ASX: $NTI) extends clinical trials in paediatric neurological disorders

Positive results from ASD and Rett Syndrome trials, $10.0 million capital raise

April 24, 2024
neurotech-international-asx-nti-receives-fda-response-on-orphan-drug-request-nti
Health Care $NTI

Neurotech International (ASX: $NTI) receives FDA response on orphan drug request

US FDA declines orphan drug status for NTI164 in PANDAS/PANS, 12-month abeyance granted for response

October 4, 2024

NTI

$NTI

Neurotech International (ASX: $NTI) to pursue targeted global partnering strategy and registration-directed initiatives in australia

Company to secure strategic partnerships for NTI164 and pursue multiple registrations in Australia

NTI

$NTI

Neurotech International (ASX: $NTI) reports positive clinical trial results in paediatric neurological disorders

Clinical trial data shows significant improvements in ASD and Rett Syndrome patients

NTI

$NTI

Neurotech International (ASX: $NTI) demonstrates significant improvements in ASD patients

Phase II/III clinical trial shows 56% improvement in ASD symptoms after 12 weeks of NTI164 therapy

NTI

$NTI

Neurotech International (ASX: $NTI) reports clinical improvement in PANDAS/PANS patients

NTI164 treatment shows significant improvements in anxiety and depression in children with PANDAS/PANS

NTI

$NTI

Neurotech International (ASX: $NTI) reports clinical benefits in rett syndrome trial

NTI164 shows significant improvement in Rett Syndrome patients after 12-week trial period

NTI

$NTI

Neurotech International (ASX: $NTI) extends clinical trials in paediatric neurological disorders

Positive results from ASD and Rett Syndrome trials, $10.0 million capital raise

Related Companies
CLEANSPACE HOLDINGS LIMITED
$CSX
RESONANCE HEALTH LIMITED
$RHT
RESMED INC
$RMD
HITIQ LIMITED
$HIQ
CONTROL BIONICS LIMITED
$CBL

ASX News, First
& Fast.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

By clicking Subscribe, you agree to our Terms & Conditions

© 2024 Stock Piper. All rights reserved

© 2024 Stock Piper.
All rights reserved

Blog

Healthcare
Materials
Real Estate
Consumer Staples
Consumer Discretionary Brief
Utilities

Company

About us
Terms of use
Privacy Policy

Support

Request Form
Contact Support
FAQ
Glossary

Socials

Facebook
Twitter
LinkedIn
© 2024 Stock Piper. All rights reserved
Social Media Auto Publish Powered By : XYZScripts.com
Join FREE Newsletter

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions